The single most important thing to understand is that pharmaceutical pricing doesn't work like a global marketplace - it's country by country, and companies will absolutely charge different prices in different places. India's court decision will help people in India access these drugs more affordably, but it won't automatically ripple outward. Pharma companies can and do maintain high prices in wealthy countries while cutting them in places where courts or governments force their hand. It's frustrating, but that's how it works.
What often gets overlooked is the enforcement question. A ruling on the books is one thing; actually making companies comply is another. Even within India, there's the question of whether pharmaceutical manufacturers will appeal, find workarounds, or just shift production priorities. Meanwhile, in the US, Europe, and most other developed countries, there's no equivalent legal mechanism that would treat drug pricing as extortion. Those countries rely on negotiation, market pressure, or government-set prices, which move much more slowly and usually result in smaller reductions, not dramatic ones.
That said, these decisions do create precedent and public conversation. When one major market like India takes a hard line, it does add pressure on companies - maybe not immediately, but over time it shapes how they think about global strategy. Other countries might reference this ruling in their own negotiations. But you're not going to wake up and see cancer drugs suddenly cut in half everywhere else. People in countries outside India will likely need to wait for their own courts or regulators to act, and honestly, that could take years or might not happen at all depending on the political and economic landscape where they live.